Owlstone Medical

Owlstone Medical is at the forefront of medical innovation with its development of Breath Biopsy®, a cutting-edge diagnostic tool designed to detect diseases from a simple breath sample. Leveraging their proprietary ReCIVA® Breath Sampler and advanced FAIMS microchip technology, Owlstone Medical is dedicated to transforming how diseases such as cancer, respiratory and liver diseases, and other significant health conditions are diagnosed and treated.

Founded with the mission to save 100,000 lives and reduce healthcare costs by $1.5 billion, Owlstone Medical is driving advancements in early detection and precision medicine. The Breath Biopsy® platform utilizes state-of-the-art chemical analysis to identify volatile organic compounds (VOCs) in breath, which are indicative of a wide array of diseases. This non-invasive approach not only enhances patient comfort but also improves the potential for early diagnosis, when treatments are typically more effective.

Owlstone Medical collaborates extensively across the healthcare spectrum, engaging in pivotal studies targeting major health issues like lung cancer, asthma, and liver disease. The company’s partnerships span multiple sectors, focusing on a variety of conditions from pulmonary hypertension to workplace exposures, to foster broad applications of its technologies.

Owlstone Medical also offers its Breath Biopsy Products and Services to academic, clinical, and pharmaceutical research partners, facilitating the development of custom breath-based diagnostics. This collaborative approach ensures that the potential of breath diagnostics is fully realized, paving the way for a future where routine screenings and precise diagnostics are more accessible and effective.